FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2133345449> ?p ?o ?g. }

• W2133345449 endingPage "3496" @default.
• W2133345449 startingPage "3490" @default.
• W2133345449 abstract "Purpose For patients with relapsed or refractory aggressive lymphoma, we hypothesized that gemcitabine-based therapy before autologous stem-cell transplantation (ASCT) is as effective as and less toxic than standard treatment. Patients and Methods We randomly assigned 619 patients with relapsed/refractory aggressive lymphoma to treatment with gemcitabine, dexamethasone, and cisplatin (GDP) or to dexamethasone, cytarabine, and cisplatin (DHAP). Patients with B-cell lymphoma also received rituximab. Responding patients proceeded to stem-cell collection and ASCT. Coprimary end points were response rate after two treatment cycles and transplantation rate. The noninferiority margin for the response rate to GDP relative to DHAP was set at 10%. Secondary end points included event-free and overall survival, treatment toxicity, and quality of life. Results For the intention-to-treat population, the response rate with GDP was 45.2%; with DHAP the response rate was 44.0% (95% CI for difference, −9.0% to 6.7%), meeting protocol-defined criteria for noninferiority of GDP (P = .005). Similar results were obtained in a per-protocol analysis. The transplantation rates were 52.1% with GDP and 49.3% with DHAP (P = .44). At a median follow-up of 53 months, no differences were detected in event-free survival (HR, 0.99; stratified log-rank P = .95) or overall survival (HR, 1.03; P = .78) between GDP and DHAP. Treatment with GDP was associated with less toxicity (P < .001) and need for hospitalization (P < .001), and preserved quality of life (P = .04). Conclusion For patients with relapsed or refractory aggressive lymphoma, in comparison with DHAP, treatment with GDP is associated with a noninferior response rate, similar transplantation rate, event-free survival, and overall survival, less toxicity and hospitalization, and superior quality of life." @default.
• W2133345449 created "2016-06-24" @default.
• W2133345449 creator A5002628051 @default.
• W2133345449 creator A5006619488 @default.
• W2133345449 creator A5008801653 @default.
• W2133345449 creator A5011221055 @default.
• W2133345449 creator A5011614506 @default.
• W2133345449 creator A5011619265 @default.
• W2133345449 creator A5013976382 @default.
• W2133345449 creator A5020540368 @default.
• W2133345449 creator A5026392434 @default.
• W2133345449 creator A5027397937 @default.
• W2133345449 creator A5029073239 @default.
• W2133345449 creator A5032098740 @default.
• W2133345449 creator A5035331881 @default.
• W2133345449 creator A5035398527 @default.
• W2133345449 creator A5037155506 @default.
• W2133345449 creator A5044632878 @default.
• W2133345449 creator A5054238326 @default.
• W2133345449 creator A5061856914 @default.
• W2133345449 creator A5062545920 @default.
• W2133345449 creator A5067291402 @default.
• W2133345449 creator A5083858828 @default.
• W2133345449 creator A5086588458 @default.
• W2133345449 creator A5091222951 @default.
• W2133345449 date "2014-11-01" @default.
• W2133345449 modified "2023-10-16" @default.
• W2133345449 title "Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12" @default.
• W2133345449 cites W1908529899 @default.
• W2133345449 cites W1912693401 @default.
• W2133345449 cites W1970400561 @default.
• W2133345449 cites W1997353354 @default.
• W2133345449 cites W2041130945 @default.
• W2133345449 cites W2068410289 @default.
• W2133345449 cites W2076668534 @default.
• W2133345449 cites W2092652286 @default.
• W2133345449 cites W2105258029 @default.
• W2133345449 cites W2111716055 @default.
• W2133345449 cites W2118895735 @default.
• W2133345449 cites W2120990323 @default.
• W2133345449 cites W2130997237 @default.
• W2133345449 cites W2137348614 @default.
• W2133345449 cites W2139401596 @default.
• W2133345449 cites W2140104756 @default.
• W2133345449 cites W2150587745 @default.
• W2133345449 cites W2330813625 @default.
• W2133345449 cites W4205736005 @default.
• W2133345449 cites W4293241248 @default.
• W2133345449 cites W8887711 @default.
• W2133345449 doi "https://doi.org/10.1200/jco.2013.53.9593" @default.
• W2133345449 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25267740" @default.
• W2133345449 hasPublicationYear "2014" @default.
• W2133345449 type Work @default.
• W2133345449 sameAs 2133345449 @default.
• W2133345449 citedByCount "325" @default.
• W2133345449 countsByYear W21333454492014 @default.
• W2133345449 countsByYear W21333454492015 @default.
• W2133345449 countsByYear W21333454492016 @default.
• W2133345449 countsByYear W21333454492017 @default.
• W2133345449 countsByYear W21333454492018 @default.
• W2133345449 countsByYear W21333454492019 @default.
• W2133345449 countsByYear W21333454492020 @default.
• W2133345449 countsByYear W21333454492021 @default.
• W2133345449 countsByYear W21333454492022 @default.
• W2133345449 countsByYear W21333454492023 @default.
• W2133345449 crossrefType "journal-article" @default.
• W2133345449 hasAuthorship W2133345449A5002628051 @default.
• W2133345449 hasAuthorship W2133345449A5006619488 @default.
• W2133345449 hasAuthorship W2133345449A5008801653 @default.
• W2133345449 hasAuthorship W2133345449A5011221055 @default.
• W2133345449 hasAuthorship W2133345449A5011614506 @default.
• W2133345449 hasAuthorship W2133345449A5011619265 @default.
• W2133345449 hasAuthorship W2133345449A5013976382 @default.
• W2133345449 hasAuthorship W2133345449A5020540368 @default.
• W2133345449 hasAuthorship W2133345449A5026392434 @default.
• W2133345449 hasAuthorship W2133345449A5027397937 @default.
• W2133345449 hasAuthorship W2133345449A5029073239 @default.
• W2133345449 hasAuthorship W2133345449A5032098740 @default.
• W2133345449 hasAuthorship W2133345449A5035331881 @default.
• W2133345449 hasAuthorship W2133345449A5035398527 @default.
• W2133345449 hasAuthorship W2133345449A5037155506 @default.
• W2133345449 hasAuthorship W2133345449A5044632878 @default.
• W2133345449 hasAuthorship W2133345449A5054238326 @default.
• W2133345449 hasAuthorship W2133345449A5061856914 @default.
• W2133345449 hasAuthorship W2133345449A5062545920 @default.
• W2133345449 hasAuthorship W2133345449A5067291402 @default.
• W2133345449 hasAuthorship W2133345449A5083858828 @default.
• W2133345449 hasAuthorship W2133345449A5086588458 @default.
• W2133345449 hasAuthorship W2133345449A5091222951 @default.
• W2133345449 hasBestOaLocation W21333454491 @default.
• W2133345449 hasConcept C126322002 @default.
• W2133345449 hasConcept C141071460 @default.
• W2133345449 hasConcept C143998085 @default.
• W2133345449 hasConcept C181199279 @default.
• W2133345449 hasConcept C185592680 @default.
• W2133345449 hasConcept C2776694085 @default.
• W2133345449 hasConcept C2778041864 @default.
• W2133345449 hasConcept C2779050716 @default.

• next